Motor effects of the partial dopamine agonist (−)‐3‐(3‐hydroxyphenyl)‐N‐n‐propylpiperidine (preclamol) in Parkinson's disease
Identifieur interne : 002423 ( Main/Exploration ); précédent : 002422; suivant : 002424Motor effects of the partial dopamine agonist (−)‐3‐(3‐hydroxyphenyl)‐N‐n‐propylpiperidine (preclamol) in Parkinson's disease
Auteurs : L. Verhagen Metman [États-Unis] ; V. H. Sethy [États-Unis] ; J. R. Roberts [États-Unis] ; D. Bravi [États-Unis] ; J. I. Hoff [États-Unis] ; M. M. Mouradian [États-Unis] ; Chase [États-Unis]Source :
- Movement Disorders [ 0885-3185 ] ; 1994.
English descriptors
Abstract
The motor effects of the partial dopamine agonist (–)‐3‐(3‐hydroxyphenyl)‐N‐n‐propylpiperidine [(–)‐3‐PPP, preclamol] were evaluated in nine patients with Parkinson's disease using a double‐blind, placebocontrolled design. (–)‐3‐PPP monotherapy had an antiparkinsonian effect in five of nine patients at a mean dose of 37 ± 10 mg intramuscularly. The co‐administration of (–)‐3‐PPP and a mildly dyskinetic dose of levodopa, infused intravenously at steady‐state, resulted in complete suppression of dyskinesias and reemergence of parkinsonian signs in two of seven patients. These dopamine antagonist effects of (–)‐3‐PPP occurred at relatively low (2.5 and 5 mg) doses. Our results suggest that partial dopamine agonists can exert agonist or antagonist activity in parkinsonian patients depending on concurrent dopaminergic tone. Although this dual action of (–)‐3‐PPP and other partial agonists could be therapeutically important on theoretical grounds, the small number of patients manifesting a clinically significant response and the frequently inconsistent effects could indicate that this class of agents may have relatively limited clinical utility.
Url:
DOI: 10.1002/mds.870090512
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Motor effects of the partial dopamine agonist (−)‐3‐(3‐hydroxyphenyl)‐N‐n‐propylpiperidine (preclamol) in Parkinson's disease</title><author><name sortKey="Metman, L Verhagen" sort="Metman, L Verhagen" uniqKey="Metman L" first="L. Verhagen" last="Metman">L. Verhagen Metman</name></author><author><name sortKey="Sethy, V H" sort="Sethy, V H" uniqKey="Sethy V" first="V. H." last="Sethy">V. H. Sethy</name></author><author><name sortKey="Roberts, J R" sort="Roberts, J R" uniqKey="Roberts J" first="J. R." last="Roberts">J. R. Roberts</name></author><author><name sortKey="Bravi, D" sort="Bravi, D" uniqKey="Bravi D" first="D." last="Bravi">D. Bravi</name></author><author><name sortKey="Hoff, J I" sort="Hoff, J I" uniqKey="Hoff J" first="J. I." last="Hoff">J. I. Hoff</name></author><author><name sortKey="Mouradian, M M" sort="Mouradian, M M" uniqKey="Mouradian M" first="M. M." last="Mouradian">M. M. Mouradian</name></author><author><name sortKey="Chase" sort="Chase" uniqKey="Chase" last="Chase">Chase</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:E254AAE527E1DD91ECB5AD86055DF6DAA5FDF03F</idno><date when="1994" year="1994">1994</date><idno type="doi">10.1002/mds.870090512</idno><idno type="url">https://api.istex.fr/document/E254AAE527E1DD91ECB5AD86055DF6DAA5FDF03F/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">002980</idno><idno type="wicri:Area/Main/Curation">002627</idno><idno type="wicri:Area/Main/Exploration">002423</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Motor effects of the partial dopamine agonist (−)‐3‐(3‐hydroxyphenyl)‐N‐n‐propylpiperidine (preclamol) in Parkinson's disease</title><author><name sortKey="Metman, L Verhagen" sort="Metman, L Verhagen" uniqKey="Metman L" first="L. Verhagen" last="Metman">L. Verhagen Metman</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Sethy, V H" sort="Sethy, V H" uniqKey="Sethy V" first="V. H." last="Sethy">V. H. Sethy</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Roberts, J R" sort="Roberts, J R" uniqKey="Roberts J" first="J. R." last="Roberts">J. R. Roberts</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Bravi, D" sort="Bravi, D" uniqKey="Bravi D" first="D." last="Bravi">D. Bravi</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Hoff, J I" sort="Hoff, J I" uniqKey="Hoff J" first="J. I." last="Hoff">J. I. Hoff</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Mouradian, M M" sort="Mouradian, M M" uniqKey="Mouradian M" first="M. M." last="Mouradian">M. M. Mouradian</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Chase" sort="Chase" uniqKey="Chase" last="Chase">Chase</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="1994">1994</date><biblScope unit="volume">9</biblScope><biblScope unit="issue">5</biblScope><biblScope unit="page" from="577">577</biblScope><biblScope unit="page" to="581">581</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">E254AAE527E1DD91ECB5AD86055DF6DAA5FDF03F</idno><idno type="DOI">10.1002/mds.870090512</idno><idno type="ArticleID">MDS870090512</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>(‐)‐3–PPP</term><term>Dyskinesias</term><term>Parkinson's disease</term><term>Partial dopamine agonist</term><term>Preclamol</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The motor effects of the partial dopamine agonist (–)‐3‐(3‐hydroxyphenyl)‐N‐n‐propylpiperidine [(–)‐3‐PPP, preclamol] were evaluated in nine patients with Parkinson's disease using a double‐blind, placebocontrolled design. (–)‐3‐PPP monotherapy had an antiparkinsonian effect in five of nine patients at a mean dose of 37 ± 10 mg intramuscularly. The co‐administration of (–)‐3‐PPP and a mildly dyskinetic dose of levodopa, infused intravenously at steady‐state, resulted in complete suppression of dyskinesias and reemergence of parkinsonian signs in two of seven patients. These dopamine antagonist effects of (–)‐3‐PPP occurred at relatively low (2.5 and 5 mg) doses. Our results suggest that partial dopamine agonists can exert agonist or antagonist activity in parkinsonian patients depending on concurrent dopaminergic tone. Although this dual action of (–)‐3‐PPP and other partial agonists could be therapeutically important on theoretical grounds, the small number of patients manifesting a clinically significant response and the frequently inconsistent effects could indicate that this class of agents may have relatively limited clinical utility.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Maryland</li></region></list><tree><country name="États-Unis"><region name="Maryland"><name sortKey="Metman, L Verhagen" sort="Metman, L Verhagen" uniqKey="Metman L" first="L. Verhagen" last="Metman">L. Verhagen Metman</name></region><name sortKey="Bravi, D" sort="Bravi, D" uniqKey="Bravi D" first="D." last="Bravi">D. Bravi</name><name sortKey="Chase" sort="Chase" uniqKey="Chase" last="Chase">Chase</name><name sortKey="Hoff, J I" sort="Hoff, J I" uniqKey="Hoff J" first="J. I." last="Hoff">J. I. Hoff</name><name sortKey="Mouradian, M M" sort="Mouradian, M M" uniqKey="Mouradian M" first="M. M." last="Mouradian">M. M. Mouradian</name><name sortKey="Roberts, J R" sort="Roberts, J R" uniqKey="Roberts J" first="J. R." last="Roberts">J. R. Roberts</name><name sortKey="Sethy, V H" sort="Sethy, V H" uniqKey="Sethy V" first="V. H." last="Sethy">V. H. Sethy</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002423 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002423 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:E254AAE527E1DD91ECB5AD86055DF6DAA5FDF03F
|texte= Motor effects of the partial dopamine agonist (−)‐3‐(3‐hydroxyphenyl)‐N‐n‐propylpiperidine (preclamol) in Parkinson's disease
}}
| This area was generated with Dilib version V0.6.23. |  |